HIV-1 Infections

15 registered clinical trials studyying HIV-1 Infections.

Status	Trial	Sponsor	Phase
Unknown	HIV PrEP Priming of Immune Effectors NCT02593409	MRC/UVRI and LSHTM Uganda Research Unit	Phase 4
Completed	TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infe NCT01281813	Janssen Sciences Ireland UC	Phase 3
Withdrawn	Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women NCT00984152	Rush University Medical Center	Phase 3
Completed	TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Ch NCT01138605	Janssen Sciences Ireland UC	Phase 2
Completed	Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV- NCT01151319	University of Oxford	Phase 1
Completed	Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children NCT01139905	The HIV Netherlands Australia Thailand Research Collaboration	Phase 2
Completed	Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) NCT01033760	ANRS, Emerging Infectious Diseases	Phase 3
Completed	Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268) NCT01078246	Merck Sharp & Dohme LLC	—
Completed	A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States NCT00799058	International Partnership for Microbicides, Inc.	Phase 1 / Phase 2
Completed	Lopinavir (LPV) Dose Reduction NCT01159275	The HIV Netherlands Australia Thailand Research Collaboration	Phase 1 / Phase 2
Completed	Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults NCT00830804	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Phase 2
Completed	Observational Data Analysis in EuroSIDA (MK-0518-058) NCT01078233	Merck Sharp & Dohme LLC	—
Completed	Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples NCT00557245	University of Washington	Phase 3
Completed	Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in NCT01074931	Abbott	—
Completed	CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients NCT01013415	University of Pennsylvania	Phase 1